glp 1 equivalency chart 55 - Comparative Analysis of A1c and Weight Reduction Potential of Subcutaneous GLP-1 Receptor Agonists in a Real-World Setting GLP-1 Comparison Chart May 2025

In January 2025, the MMIT Index team surveyed payers representing commercial, Medicare, and Medicaid lives to gather insights into the potential impact of GLP-1 drugs anticipated expansions into indications like OSA

Branded GLP-1 medications are FDA-approved finished drug products that have completed the full regulatory review and approval process for their indicated uses

The bottom line on side effects: Retatrutide is not dramatically riskier for most people, but it is not a simple lateral move

As these medications slow gastric emptying, relative contraindications include history of recurrent pancreatitis and gastroparesis

P R Health Sci J

Patients and healthcare systems are eager for cheaper yet effective options